Skip to main content

Clinical trial 1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with
clinical benefit

Organ solid tumors
Trial status Trial open for recruitment
Trial type
Prospective interventional
Phase Trial phase 1
Academic trial Non
Sponsor Boehringer Ingelheim
EudraCT Identifier 2015-001111-12
Inclusion criteria any line RECIST 1.1
Last update

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more